| Literature DB >> 28031714 |
Yuka Kudo1, Atsuo Nakagawa2, Taisei Wake3, Natsumi Ishikawa3, Chika Kurata3, Mizuki Nakahara4, Teruo Nojima5, Masaru Mimura3.
Abstract
BACKGROUND: Despite available treatments, major depression is a highly heterogeneous disorder, which leads to problems in classification and treatment specificity. Previous studies have reported that personality traits predict and influence the course and treatment response of depression. The Temperament and Personality Questionnaire (T&P) assesses eight major constructs of personality traits observed in those who develop depression. The aim of this study was to investigate the influence of T&P's eight constructs on the treatment outcome of depressed patients. PATIENTS AND METHODS: A preliminary 6-month prospective study was conducted with a sample of 51 adult patients with a diagnosis of major depressive disorder (MDD) without remarkable psychomotor disturbance using the Diagnostic and Statistical Manual of Mental Disorders, fourth edition. All patients received comprehensive assessment including the T&P at baseline. We compared each T&P construct score between patients who achieved remission and those who did not achieve remission after 6 months of treatment for depression using both subjective and objective measures. All 51 (100%) patients received the 6-month follow-up assessment.Entities:
Keywords: Temperament and Personality Questionnaire; classification; personal reserve; rejection sensitivity; self-criticism; treatment outcome
Year: 2016 PMID: 28031714 PMCID: PMC5182045 DOI: 10.2147/NDT.S123788
Source DB: PubMed Journal: Neuropsychiatr Dis Treat ISSN: 1176-6328 Impact factor: 2.570
Figure 1Flowchart of patient selection process for the study.
Comparison of demographics and clinical characteristics between remitters and non-remitters
| Demographics and clinical characteristics | Remitter (n=23) | Non-remitter (n=28) | Total (n=51) |
|---|---|---|---|
| Age (years) | 40.3 (12.6) | 41.5 (10.8) | 40.9 (11.5) |
| Women | 17 (73.9%) | 18 (64.3%) | 35 (68.6%) |
| Education (years) | 14.9 (2.4) | 14.1 (2.2) | 14.5 (2.3) |
| Employed | 13 (56.5%) | 20 (71.4%) | 33 (64.7%) |
| Unemployed | 3 (13.0%) | 5 (17.8%) | 8 (15.7%) |
| Housewife and student | 7 (30.4%) | 3 (10.7%) | 10 (19.6%) |
| Marital status | |||
| Married | 13 (56.5%) | 11 (39.3%) | 24 (47.1%) |
| Separated, divorced, widowed | 1 (4.3%) | 4 (14.3%) | 5 (9.8%) |
| Single | 9 (39.1%) | 13 (46.4%) | 22 (43.1%) |
| Cohabiting | 20 (87.0%) | 19 (67.9%) | 39 (76.5%) |
| Family history of psychiatric disorders | 8 (34.7%) | 13 (46.4%) | 21 (41.2%) |
| Total number of lifetime depressive episodes | 1.4 (0.8) | 1.7 (1.4) | 1.6 (1.2) |
| Median duration of current depressive episode (months) | 7 | 13.5 | 9 |
| Depression severity at baseline | |||
| GRID-HAMD21 | 10.0 (7.9) | 17.1 (7.0) | 13.9 (8.2) |
| BDI-II | 17.8 (12.1) | 27.8 (11.0) | 23.6 (12.6) |
| QIDS-SR16 | 8.8 (6.9) | 14.0 (5.1) | 11.6 (6.5) |
| Degree of functional impairment at baseline | |||
| SDS total | 11.8 (7.8) | 16.2 (7.3) | 14.2 (7.8) |
| SDS work domain | 4.5 (3.2) | 6.1 (2.9) | 5.3 (3.1) |
| SDS social life domain | 4.5 (2.8) | 5.9 (2.8) | 5.3 (2.8) |
| SDS family life domain | 2.9 (2.7) | 4.2 (2.7) | 3.6 (2.7) |
| Number of antidepressant treatment courses for current episode | |||
| 0 | 0 (0.0%) | 1 (3.6%) | 1 (2.0%) |
| 1–2 | 20 (87.0%) | 14 (50.0%) | 34 (66.7%) |
| 3–4 | 2 (8.7%) | 11 (39.2%) | 13 (25.4%) |
| 5 or more | 1 (4.3%) | 2 (7.1%) | 3 (5.9%) |
| Duration of antidepressant treatment for current episode | |||
| <6 months | 16 (69.6%) | 12 (42.9%) | 28 (54.9%) |
| 6 months to 1 year | 4 (17.3%) | 3 (10.7%) | 7 (13.7%) |
| 1–2 years | 1 (4.3%) | 6 (21.4%) | 7 (13.7%) |
| >2 years | 2 (8.7%) | 7 (25.0%) | 9 (17.6%) |
| Used antidepressant at baseline | |||
| SSRI | |||
| Sertraline | 15 (65.2%) | 13 (46.4%) | 28 (54.9%) |
| Paroxetine | 0 (0.0%) | 2 (7.1%) | 2 (3.9%) |
| Fluvoxamine | 1 (4.3%) | 0 (0.0%) | 1 (2.0%) |
| Escitalopram | 2 (8.7%) | 0 (0.0%) | 2 (3.9%) |
| SNRI | |||
| Duloxetine | 2 (8.7%) | 3 (10.7%) | 5 (9.8%) |
| Milnacipran | 1 (4.3%) | 1 (3.6%) | 2 (3.9%) |
| TCA | |||
| Amoxapine | 0 (0.0%) | 1 (3.6%) | 1 (2.0%) |
| Nortriptyline | 0 (0.0%) | 1 (3.6%) | 1 (2.0%) |
| Amitriptyline | 1 (4.3%) | 1 (3.6%) | 2 (3.9%) |
| Other | |||
| Mirtazapine | 1 (4.3%) | 3 (10.7%) | 4 (7.8%) |
| Trazodone | 0 (0.0%) | 1 (3.6%) | 1 (2.0%) |
| Mianserin | 0 (0.0%) | 1 (3.6%) | 1 (2.0%) |
| Treatment modality at 6 months post baseline | |||
| Antidepressant therapy only | 20 (87.0%) | 25 (89.3%) | 45 (88.2%) |
| Combination of antidepressant therapy and CBT | 3 (13.0%) | 2 (7.1%) | 5 (9.8%) |
| CBT only | 0 (0.0%) | 1 (3.6%) | 1 (2.0%) |
Notes: Data are shown as mean (SD) or n (%). Remitters means patients who achieved remission by the 6-month assessment (GRID-HAMD21 ≤7).
Abbreviations: BDI-II, Beck Depression Inventory, Second Edition; CBT, cognitive behavioral therapy; GRID-HAMD21, 21-item GRID-Hamilton Depression Rating Scale; QIDS-SR16, 16-Item Quick Inventory Depressive Symptomatology (Self-Report); SDS, Sheehan Disability Scale; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressants.
Scores on treatment outcome measures
| Baseline | 6 months | ||
|---|---|---|---|
| Depression severity | |||
| GRID-HAMD21 | 13.9 (8.2) | 9.9 (7.5) | 0.001 |
| BDI-II | 23.6 (12.6) | 16.9 (13.8) | 0.001 |
| QIDS-SR16 | 11.6 (6.5) | 8.2 (5.5) | <0.001 |
| Functional impairment | |||
| SDS total | 14.2 (7.8) | 10.1 (7.9) | <0.001 |
| SDS work domain | 5.3 (3.1) | 4.0 (3.3) | 0.001 |
| SDS social life domain | 5.3 (2.8) | 3.7 (2.9) | <0.001 |
| SDS family life domain | 3.6 (2.7) | 2.4 (2.4) | 0.001 |
Notes: Data are shown as mean (SD).
Paired-samples t-test.
Abbreviations: BDI-II, Beck Depression Inventory, Second Edition; GRID-HAMD21, 21-item GRID-Hamilton Depression Rating Scale; QIDS-SR16, 16-Item Quick Inventory Depressive Symptomatology (Self-Report); SDS, Sheehan Disability Scale.
Comparison of T&P construct scores between remitters and non-remitters (n=51)
| Characteristics | Remitter | Non-remitter | ||
|---|---|---|---|---|
| Anxious worrying | 14.2 (5.1) | 15.3 (4.5) | −0.82 | 0.42 |
| Personal reserve | 8.4 (6.0) | 12.3 (5.3) | −2.41 | 0.02 |
| Perfectionism | 12.2 (5.8) | 12.7 (5.0) | −0.36 | 0.72 |
| Irritability | 10.2 (6.0) | 10.7 (5.6) | −0.28 | 0.78 |
| Social avoidance | 13.8 (4.0) | 15.0 (4.5) | −1.03 | 0.31 |
| Rejection sensitivity | 5.8 (4.6) | 8.6 (4.8) | −2.14 | 0.04 |
| Self-criticism | 12.8 (4.2) | 15.4 (3.5) | −2.46 | 0.02 |
| Self-focused | 4.0 (2.9) | 4.4 (3.3) | −0.44 | 0.66 |
Notes: Data are shown as mean (SD).
Student’s t-test.
Abbreviation: T&P, Temperament and Personality Questionnaire.
Logistic regression analysis of remitters and non-remitters for major depression (n=51)
| Variables | Odds ratio | 95% CI | ||
|---|---|---|---|---|
| Personal reserve | 1.15 | 1.02–1.31 | 7.84 | 0.03 |
| GRID-HAMD21 score at baseline | 1.17 | 1.05–1.30 | 4.97 | 0.01 |
|
| ||||
| Rejection sensitivity | 1.08 | 0.93–1.25 | 5.91 | 0.30 |
| GRID-HAMD21 score at baseline | 1.14 | 1.03–1.27 | 1.09 | 0.02 |
|
| ||||
| Self-criticism | 1.10 | 0.93–1.30 | 5.13 | 0.28 |
| GRID-HAMD21 score at baseline | 1.14 | 1.02–1.27 | 1.16 | 0.02 |
Note:
Likelihood ratio test.
Abbreviations: CI, confidence interval; GRID-HAMD21, 21-item GRID-Hamilton Depression Rating Scale.